Lipoxygenase

ML351 (Standard) is the analytical standard of ML351 (HY-111310). This product is intended for research and analytical applications. ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC₅₀ of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2. ML351 prevents dysglycemia and reduces β-cell oxidative stress in nonobese diabetic mouse model of T1D.

Pectolinarigenin (Standard) is the analytical standard of Pectolinarigenin. This product is intended for research and analytical applications. Pectolinarigenin is an orally active dual inhibitor of COX-2/5-LOX with anti-inflammatory, antioxidant, antitumor and neuroprotective activities. Pectolinarigenin exerts neuroprotective and anti-inflammatory effects on astrocyte inflammation via the NFκB and MAPK pathways. Pectolinarigenin inhibits LPS-induced phosphorylation of ERK1/2, N-FκB and p38MAPK, directly inhibits the enzymatic activity or binding of COX-2, 5-LOX and HIF-1α, and reduces the level of XIAP. Pectolinarigenin modifies Keap1 to promote nuclear accumulation of Nrf2, induces ARE-mediated antioxidant enzyme expression, and possesses direct free radical scavenging activity. Pectolinarigenin reduces the release of NO, proinflammatory mediators and leukotrienes, and increases the level of IL-10. Pectolinarigenin induces G₂/M cell cycle arrest, apoptosis (Apoptosis) and autophagy (Autophagy) via the PI3K/AKT/mTOR signaling pathway. Pectolinarigenin reduces renal crystal deposition and inhibits melanin synthesis. Pectolinarigenin inhibits inflammation and alleviates allergy in mouse models of inflammation. Pectolinarigenin alleviates renal injury, inflammation and oxidative stress in mice by inhibiting HIF-1α activity. Pectolinarigenin can be used for the research of neurodegenerative diseases, inflammatory/allergic diseases, calcium oxalate nephrocalcinosis, gastric cancer, melasma, post-inflammatory diseases and chloasma.

L-651896 is a compound with anti-inflammatory and antiproliferative activities that inhibits 5-lipoxygenase and cyclooxygenase, thereby reducing the production of leukotrienes and prostaglandins. L-651896 can be used in the study of skin diseases and other inflammatory diseases.

PD 127443 is an inhibitor of 5-lipoxygenase and cyclooxygenase. PD 127443 has anti-inflammatory activity.

Picralinal (Picraline, 16-de(acetoxymethyl)-16-formyl-) is a Triterpenoids product that can be isolated from the whole plants of Scilla scilloides..

Tremulacin is a 5-LOX inhibitor. Tremulacin reduces the biosynthesis of LTB₄ and slow-reacting substances of anaphylaxis. Tremulacin alleviates carrageenan-induced paw edema in rats, croton oil-induced ear edema in mice, and acetic acid-induced writhing response in mice. Tremulacin inhibits TNF-α-stimulated ROS production and MMP-1 expression, and promotes collagen secretion in human dermal fibroblasts. Tremulacin is investigated for studies on inflammation-related diseases.

Masoprocol (Standard) is the analytical standard of Masoprocol. This product is intended for research and analytical applications. Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes.

Docebenone (Standard) is the analytical standard of Docebenone. This product is intended for research and analytical applications. Docebenone (AA 861) is a potent, selective and orally active 5-LO (5-lipoxygenase) inhibitor.

LP117 is a novel and potent inhibitor of 5-Lipoxygenase (5-LO) product synthesis with an IC₅₀ of 1.1 μM.

Lagunamycin is a 5-lipoxygenase inhibitor isolated from the culture medium of Streptomyces sp. AA0310. Lagunamycin has a significant inhibitory activity against rat 5-lipoxygenase with an IC50 value of 6.08 μM. Lagunamycin can effectively inhibit 5-lipoxygenase without causing lipid peroxidation, indicating that it has an effective inhibitory effect without causing side effects.

BI-L-357 is a succinate derived from BI-L-226 that acts as a precursor, enhances oral bioavailability and inhibits 5-lipoxygenase-mediated leukotriene production.

ZLJ-6 is a dual COX and 5-LOX inhibitor with oral activity. The IC₅₀ values for COX-1, COX-2 and 5-LOX were 0.73, 0.31 and 0.99 μM, respectively. ZLJ-6 has anti-inflammatory and analgesic activity.

S-2474 is an inhibitor of COX-2 and 5-lipoxygenase (5-LO), with IC₅₀s of 11 nM and 27 μM for COX-2 and COX-1 in human intact cells, and used as a nonsteroidal anti-inflammatory agent.

Asperenone is an inhibitor of 15-lipoxygenase (15-LOX) with an IC₅₀ value of 0.3 mM. It is also an inhibitor of platelet aggregation, with an IC₅₀ value of 0.23 mM. Additionally, Asperenone has antifungal activity and can inhibit the growth of pathogenic fungi Ophiostoma crassivaginatum and O. piliferum. Asperenone can be used in the research of cardiovascular diseases and anti-infection fields.

5-LOX-IN-9 is a 5-lipoxygenase and cyclooxygenase inhibitor, with an IC₅₀ of 0.2 pM against guinea pig 5-LOX and an IC₅₀ of 0.7 pM against bovine COX. 5-LOX-IN-9 inhibits 5-lipoxygenase via a redox-mediated mechanism. 5-LOX-IN-9 inhibits cyclooxygenase through hydrogen donor action and hydrophobicity-dependent activity.

(-)-Bornyl ferulate is a 5-lipoxygenase and COX inhibitor with IC₅₀s of 10.4 μM and 12.0 μM, respectively.

Fenleuton is a 5-lipoxygenase inhibitor. Fenleuton is promising for research of leukotriene-mediated inflammatory diseases.

2'-Hydroxy-3,4-dimethoxychalcone is a chalcone derivative and lipoxygenase inhibitor with an IC₅₀ of 67.5 μM. 2'-Hydroxy-3,4-dimethoxychalcone acts as a radical scavenger that scavenges DPPH stable free radical, superoxide anion radical, and hydroxyl radical. 2'-Hydroxy-3,4-dimethoxychalcone scavenges hydrogen peroxide and inhibits linoleic acid lipid peroxidation. 2'-Hydroxy-3,4-dimethoxychalcone can be used for research on oxidative damage and inflammatory diseases.

(2S,5S)-CMI-392 is the absolute configuration of CMI-392 (HY-19205A). CMI-392 is an orally active dual 5-lipoxygenase inhibitor and platelet-activating factor receptor (PAFR) antagonist, with an IC₅₀ of 10 nM for human PAF receptor and an IC₅₀ of 100 nM for rat 5-lipoxygenase. CMI-392 blocks PAF receptor binding, inhibits leukotriene synthesis, attenuates PAF-induced hemoconcentration, and suppresses arachidonic acid- and TPA-induced ear swelling in mice. CMI-392 reduces inflammatory cell infiltration, decreases MPO levels, alleviates ocular inflammation, and improves dextran sulfate sodium-induced colitis. CMI-392 can be used in the research of inflammatory and immune-related diseases such as colitis and atopic dermatitis.

FerroLOXIN-1 is a potent inhibitor of 15LOX-2 that selectively blocked production of pro-ferroptotic HOO-ETE-PE and protected against RSL3-induced ferroptosis. FerroLOXIN-1 closely interacted therein with 15LOX-2 only, and in particular with Y154, N155, W158.